The blockbuster diabetes drug Ozempic - also sold as the obesity drug Wegovy - significantly reduces the risk of kidney failure and death for people with type 2 diabetes and chronic kidney disease. Scientists are optimistic about its potential broader population use.
Participants receiving semaglutide injections were 24% less likely to experience major kidney disease events and 29% less likely to die from heart attacks. Dr. Parikh emphasizes the deep link between kidney disease and heart disease.
[
add
]
[
|
|
...
]